|May 20, 2022|
|May 16, 2022|
|May 09, 2022|
|April 08, 2022|
|March 31, 2022|
|March 30, 2022|
|March 17, 2022|
|March 16, 2022|
|March 01, 2022|
|February 28, 2022|
Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the Future; Announces Combination of its Biosimilars Portfolio with Biocon Biologics in Exchange for up to $3.335 Billion Representing an Attractive Multiple to Viatris of 16.5x the Company's Biosimilars 2022E Adjusted EBITDA(1), the First in a Series of Expected Initiatives Anticipated to Unlock up to an Additional $6 Billion in Pre-tax Proceeds by the End of 2023; Board of Directors Authorizes a Share Repurchase Program of up to $1 Billion, Maintaining Company Commitment to Return Capital to Shareholders
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.
Copyright © 2022. All rights reserved.